Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.
Fiche publication
Date publication
mars 2024
Journal
Gland surgery
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
Tous les auteurs :
Ye G, Chen P, Liu X, He T, Pivot X, Pan R, Zhou D, Zhu L, Zhang K, Li W, Yang S, Lin J, Cai G, Huang H
Lien Pubmed
Résumé
The effectiveness and safety of pyrotinib have been substantiated in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC). However, the role of pyrotinib as a single HER2 blockade in neoadjuvant setting among BC patients has not been studied. The objective of this study was to evaluate the efficacy and tolerability of pyrotinib plus taxanes as a novel neoadjuvant regimen in patients with HER2-positive early or locally advanced BC.
Mots clés
Pyrotinib, breast cancer (BC), chemotherapy, human epidermal growth factor receptor 2 (HER2), neoadjuvant therapy
Référence
Gland Surg. 2024 03 27;13(3):374-382